KVP Capital Advisors, LP
CIK 1858198 · SEC EDGAR で表示 ↗
- ポートフォリオ評価額
- $136.2M
- ポジション
- 35
- 時点
- 2026年6月30日
13F価値別で9,443件中 #7,684 位 · 81.4% トップ
ポートフォリオ価値 前期比: +1.7% 13Fは現金を公開しない
- 上位10銘柄のウェイト
- 57.41%
- 上位25銘柄のウェイト
- 89.22%
- 1%超のポジション
- 32
- 実効ポジション数
- 22.2
13Fのロングエクイティ保有のみに基づく(現金、債券、ショートは非公開)
ターオーバー Q2 2026: 13.86% 推定買付額 $18,714,663 · 推定売付額 $37,982,560
- 新規ポジション
- 6
- 増加
- 2
- 減少
- 2
- クローズ
- 3
このページについて
セクター別内訳
Healthcare
100.0%
ポートフォリオ全体 35 ポジション
| タイプ | 連続 | 8四半期トレンド | |||||
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $14,362,491 | 10.54% | 42,900 | $540,540 | |||
| WHWK Whitehawk Therapeutics, Inc. - Common Stock | $9,920,266 | 7.28% | 2,165,997 | $2,447,576 | |||
| ERAS Erasca, Inc. - Common Stock | $8,335,600 | 6.12% | 455,000 | $2,834,400 | 上昇 ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $7,721,100 | 5.67% | 414,000 | $2,782,080 | |||
| STRO Sutro Biopharma, Inc. - Common Stock | $7,522,290 | 5.52% | 226,575 | $1,878,307 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $7,198,053 | 5.28% | 230,264 | $2,380,930 | |||
| MBX MBX Biosciences, Inc. - Common Stock | $6,708,125 | 4.92% | 121,524 | $3,080,634 | |||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $6,496,740 | 4.77% | 53,000 | $910,540 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $5,403,790 | 3.97% | 133,000 | $1,214,290 | |||
| TNDM Tandem Diabetes Care, Inc. - Common Stock | $4,542,090 | 3.33% | 301,000 | 上昇 ×1 | |||
| IRON Disc Medicine, Inc. - Common Stock | $4,260,405 | 3.13% | 58,250 | $535,900 | |||
| SVRA Savara, Inc. - Common Stock | $3,728,525 | 2.74% | 605,280 | $423,696 | |||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $3,543,480 | 2.60% | 102,000 | 上昇 ×1 | |||
| INSM Insmed Incorporated - Common Stock | $3,038,350 | 2.23% | 28,497 | $-1,621,479 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $3,019,178 | 2.22% | 462,355 | $1,659,854 | |||
| IDYA IDEAYA Biosciences, Inc. - Common Stock | $2,970,419 | 2.18% | 79,700 | $314,815 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $2,946,000 | 2.16% | 300,000 | $405,000 | |||
| AXSM Axsome Therapeutics, Inc. - Common Stock | $2,937,240 | 2.16% | 12,000 | $-3,181,284 | 下落 ×1 | ||
| DSGN Design Therapeutics, Inc. - Common Stock | $2,676,950 | 1.96% | 185,000 | 上昇 ×1 | |||
| UTHR United Therapeutics Corporation - Common Stock | $2,573,693 | 1.89% | 4,750 | $-242,962 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $2,475,000 | 1.82% | 45,000 | $262,800 | |||
| IMMX Immix Biopharma, Inc. - Common Stock | $2,375,661 | 1.74% | 230,423 | $276,507 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $2,296,250 | 1.69% | 125,000 | $-148,750 | |||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $2,270,853 | 1.67% | 84,168 | 上昇 ×1 | |||
| DRUG Bright Minds Biosciences Inc. - common stock | $2,233,273 | 1.64% | 31,813 | $-88,122 | |||
| TVTX Travere Therapeutics, Inc. - Common Stock | $2,215,590 | 1.63% | 39,000 | $-488,020 | 下落 ×1 | ||
| ZURA Zura Bio Limited - Class A Ordinary shares | $2,201,455 | 1.62% | 373,128 | $-18,657 | |||
| ARTV Artiva Biotherapeutics, Inc. - Common Stock | $1,940,000 | 1.42% | 200,000 | 上昇 ×1 | |||
| NKTR Nektar Therapeutics - Common Stock | $1,877,889 | 1.38% | 26,900 | $-57,566 | |||
| CMPX Compass Therapeutics, Inc. - Common Stock | $1,688,490 | 1.24% | 771,000 | $-956,510 | 上昇 ×1 | ||
| CABA Cabaletta Bio, Inc. - Common Stock | $1,571,890 | 1.15% | 505,431 | $212,281 | |||
| VERA Vera Therapeutics, Inc. - Class A Common Stock | $1,403,157 | 1.03% | 32,700 | $87,636 | |||
| EOLS Evolus, Inc. - Common Stock | $1,041,000 | 0.76% | 150,000 | 上昇 ×1 | |||
| CELC Celcuity Inc. - Common Stock | $418,480 | 0.31% | 4,000 | $-38,080 | |||
| VYNE VYNE Therapeutics Inc. - Common Stock | $325,709 | 0.24% | 500,551 | $26,630 | |||
| 一致なし | |||||||
最大の新規投資
今四半期に新規開設されたポジション、大きい順。
上位変動銘柄(四半期比)
解消済みポジション
企業イベント(合併、上場廃止)を含む — 全ての離脱が売りとは限らない
クローズド・ポジションは13F報告の変更を反映しています。インデックス・マネージャーの場合、これらは能動的な決定ではなく、機械的なもの(上場廃止、M&A、インデックスのリバランス)であることがよくあります。